Human IL6 enhances leptin action in mice

[1]  M. Febbraio,et al.  Muscle as an endocrine organ: focus on muscle-derived interleukin-6. , 2008, Physiological reviews.

[2]  U. Smith,et al.  Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice , 2008, Diabetologia.

[3]  Heike Münzberg,et al.  Mechanisms of leptin action and leptin resistance. , 2008, Annual review of physiology.

[4]  A. Krook,et al.  Role of interleukin‐6 signalling in glucose and lipid metabolism , 2007, Acta physiologica.

[5]  E. Van Obberghen,et al.  SOCS proteins causing trouble in insulin action , 2007, Acta physiologica.

[6]  B. Pedersen.  IL-6 signalling in exercise and disease. , 2007, Biochemical Society transactions.

[7]  B. Pedersen,et al.  Physiological roles of muscle-derived interleukin-6 in response to exercise , 2007, Current opinion in clinical nutrition and metabolic care.

[8]  M. Febbraio.  gp130 receptor ligands as potential therapeutic targets for obesity. , 2007, The Journal of clinical investigation.

[9]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[10]  B. Pedersen,et al.  Interleukin-6 Regulation of AMP-Activated Protein Kinase , 2006, Diabetes.

[11]  B. Pedersen,et al.  The role of IL-6 in mediating the anti-inflammatory effects of exercise. , 2006, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[12]  D. James,et al.  Interleukin-6 Increases Insulin-Stimulated Glucose Disposal in Humans and Glucose Uptake and Fatty Acid Oxidation In Vitro via AMP-Activated Protein Kinase , 2006, Diabetes.

[13]  E. Ropelle,et al.  Exercise Improves Insulin and Leptin Sensitivity in Hypothalamus of Wistar Rats , 2006, Diabetes.

[14]  M. Febbraio,et al.  Ciliary neurotrophic factor suppresses hypothalamic AMP-kinase signaling in leptin-resistant obese mice. , 2006, Endocrinology.

[15]  A. Chait,et al.  Reciprocal and Coordinate Regulation of Serum Amyloid A Versus Apolipoprotein A-I and Paraoxonase-1 by Inflammation in Murine Hepatocytes , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[16]  C. Gabay,et al.  Interleukin-6 and chronic inflammation , 2006, Arthritis research & therapy.

[17]  A. M. Etgen,et al.  Critical role of STAT3 in leptin's metabolic actions. , 2006, Cell metabolism.

[18]  S. Akira,et al.  Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. , 2006, Cell metabolism.

[19]  Xueying Lin,et al.  Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth. , 2006, The Journal of clinical investigation.

[20]  R. Mooney,et al.  Interleukin-6 depletion selectively improves hepatic insulin action in obesity. , 2005, Endocrinology.

[21]  K. Migita,et al.  An active metabolite of leflunomide, A77 1726, inhibits the production of serum amyloid A protein in human hepatocytes. , 2005, Rheumatology.

[22]  M. Febbraio,et al.  Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. , 2005, American journal of physiology. Endocrinology and metabolism.

[23]  S. Schneider,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(11):5577–5582 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2004-0603 Interleukin-6 Regulates Human Adipose Tissue Lipid Metabolism and Leptin Produc , 2022 .

[24]  M. Febbraio,et al.  Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. , 2004, Diabetes.

[25]  Mitchell J. Anderson,et al.  Interleukin-6 and tumor necrosis factor-α are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness , 2004, Diabetologia.

[26]  G. Cline,et al.  Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. , 2004, Diabetes.

[27]  B. Jenkins,et al.  Acquiring signalling specificity from the cytokine receptor gp130. , 2004, Trends in genetics : TIG.

[28]  M. G. Myers.  Leptin receptor signaling and the regulation of mammalian physiology. , 2004, Recent progress in hormone research.

[29]  T. Zimmers,et al.  Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. , 2003, Diabetes.

[30]  B. Saltin,et al.  Interleukin-6 stimulates lipolysis and fat oxidation in humans. , 2003, The Journal of clinical endocrinology and metabolism.

[31]  Bente Klarlund Pedersen,et al.  Exercise and IL‐6 infusion inhibit endotoxin‐induced TNF‐α production in humans , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  T. Zimmers,et al.  Suppressor of Cytokine Signaling-3 (SOCS-3), a Potential Mediator of Interleukin-6-dependent Insulin Resistance in Hepatocytes* , 2003, The Journal of Biological Chemistry.

[33]  S. Rose-John,et al.  Signaling of Human Ciliary Neurotrophic Factor (CNTF) Revisited , 2003, The Journal of Biological Chemistry.

[34]  E. Derman,et al.  IL-6-overexpression brings about growth impairment potentially through a GH receptor defect. , 2002, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[35]  R. Mooney,et al.  Interleukin-6 induces cellular insulin resistance in hepatocytes. , 2002, Diabetes.

[36]  R. Ahima,et al.  Divergent effects of leptin in mice susceptible or resistant to obesity. , 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[37]  J. Jansson,et al.  Intracerebroventricular interleukin-6 treatment decreases body fat in rats. , 2002, Biochemical and biophysical research communications.

[38]  C. Ohlsson,et al.  Interleukin-6-deficient mice develop mature-onset obesity , 2002, Nature Medicine.

[39]  C Bogardus,et al.  Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. , 2001, Obesity research.

[40]  Bruce M. Spiegelman,et al.  Obesity and the Regulation of Energy Balance , 2001, Cell.

[41]  B. Saltin,et al.  Production of interleukin‐6 in contracting human skeletal muscles can account for the exercise‐induced increase in plasma interleukin‐6 , 2000, The Journal of physiology.

[42]  B. Pedersen,et al.  Cytokines in Aging and Exercise , 2000, International journal of sports medicine.

[43]  M. White,et al.  Irs-2 coordinates Igf-1 receptor-mediated β-cell development and peripheral insulin signalling , 1999, Nature Genetics.

[44]  J. Habener,et al.  Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob/ob mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[45]  F E Bloom,et al.  Modulation of Hypothalamic–Pituitary–Adrenal Function by Transgenic Expression of Interleukin-6 in the CNS of Mice , 1997, The Journal of Neuroscience.

[46]  T. Tatsumi,et al.  Interleukin-6 overexpression cannot generate serious disorders in severe combined immunodeficiency mice. , 1997, Clinical immunology and immunopathology.

[47]  G. Ciliberto,et al.  Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. , 1994, Blood.

[48]  T. Hirano,et al.  The role of interleukin 6 in plasmacytomagenesis. , 1992, Ciba Foundation symposium.

[49]  J. Miyazaki,et al.  IgG1 plasmacytosis in interleukin 6 transgenic mice. , 1989, Proceedings of the National Academy of Sciences of the United States of America.